tbuckley/cabot-search huggingface dataset:
Acne and Alopecia.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vidarabine therapy for severe herpesvirus infections. An unusual syndrome of chronic varicella and transient immunologic deficiency
Authors: M. D. Aronson
Journal: JAMA (1976)

Six patients with severe herpesvirus infections were successfully treated with vidarabine. One patient had a previously undescribed syndrome of chronic cutaneous varicella infection of eight months' duration, associated with transient but complete suppression of lymphocyte response to conconavalin A. Other diagnoses were severe varicella pneumonia, progressive cytomegalovirus pneumonia associated with acute lymphocytic leukemia, herpes simplex encephalitis, severe zoster associated with stage IV lymphoma, and disseminated herpes simplex in a patient receiving high doses of steroids. All patients showed cessation of new lesions or abrupt clinical improvement between days 2 and 4 after initiation of therapy, and all were cured of their clinical infection. Dramatic improvement in all of our patients and the minimal toxicity observed make vidarabine suitable for use in severe herpesvirus infections. (<i>JAMA</i>235:1339-1342, 1976)
Die neurologische Forschungsrichtung in der Psychopathologie und andere Aufsätze.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Waterborne Outbreak Control: Which Disinfectant?
Authors: Elmer W. Akin, John C. Hoff, Edwin C. Lippy
Journal: Environmental Health Perspectives (1982)

Drinking water disinfection was shown to be an important public health measure around the turn of the century. In the United States, it was perhaps the single most important factor in controlling typhoid fever, a waterborne disease that was rampant throughout the world during the last century. It may also be assumed that disinfection was important in limiting the number of cases of other diseases known to be capable of waterborne transmission, i.e., cholera, amebiasis, shigellosis, salmonellosis, and hepatitis A. Even though modern treatment has eliminated water as a major vehicle of infectious disease transmission, outbreaks still occur. In fact, the annual number has been increasing since 1966. Interruption in chlorination or failure to achieve adequate levels of chlorine residual is the most often identified deficiency of the involved water supplies. This finding indicates that waterborne microbial pathogens remain as a potential health threat and underscores the importance of disinfection. From the outset, chlorination has been the drinking water disinfectant of choice in the country. Numerous studies have demonstrated its ability to inactivate bacterial, viral, and protozoal pathogens when applied under proper conditions. However, the finding that chlorinated organics that are potentially carcinogenic are formed has prompted an evaluation of alternative disinfectants. The viable alternatives to chlorine currently under consideration for widespread use are ozone, chlorine dioxide, and chloramines. In terms of biocidal efficiency, ozone is the most potent of the three. Chlorine dioxide is about the equivalent of free chlorine in the hypochlorous acid form but much more efficient than the hypochlorite form of free chlorine. The chloramines are weaker biocides than hypochlorite. Although this general order of ranking of efficiency holds for diverse types of microorganisms, quantitative comparisons vary with different microorganisms and experimental conditions.
Pollutants as Developmental Toxicants in Aquatic Organisms
Authors: Judith S. Weis, Peddrick Weis
Journal: Environmental Health Perspectives (1987)

Pollutants, by disrupting metabolic processes, can interfere with development, and, at critical periods of development, can act as teratogens. Such interference with normal development can be used as a bioassay. Some screening tests are based on this phenomenon. As teratogens, pollutants are fairly nonspecific. Many different classes may elicit the same developmental responses. Mechanisms of teratogenicity include disruption of mitosis, interference with transcription and translation, metabolic disturbances in energy utilization, and nutritional deficits. These in turn interfere with cell interactions, migration, and growth. In aquatic organisms, environmental conditions can be critical. Interactions of pollutant effects with salinity and with temperature have been reported. Interactions between toxicants have also been studied; both synergism and antagonism have been reported. Most reports of teratogenesis have been qualitative. Quantitation has usually been in the form of percentages of embryos affected, but when severity of effect is indexed, more critical analysis is allowed. When effects of other developmental processes such as growth are analyzed, quantitation is readily achieved. Regeneration is an especially useful model of both differentiation and growth. These two components of regeneration can be separately analyzed. Dose-response relationships are readily apparent. In comparison to mammalian embryos, the use of embryos of many aquatic species for testing toxicants has certain advantages, including lower cost and maintenance and shorter development times. They respond to many of the same teratogens. A special advantage is availability for continual examination during development so that abnormalities can be observed and recorded as they arise.
T Cells Targeting MAGE-A4 Shrink Tumors
Journal: Cancer Discovery (2020)

Abstract Autologous T cells engineered to target the MAGE-A4 cancer testis antigen successfully shrank a wide range of solid tumors with a manageable toxicity profile. In a phase I trial, the therapy, ADP-A2M4, showed the most promise in synovial sarcoma, yielding a disease control rate of around 90%.
Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial
Authors: Jasmohan Bajaj, Patrick Yeramian, Edith Gavis, Andrew Fagan, James Fischer, Guadalupe Garcia-Tsao, Paolo Angeli, Denise Smith, Jonathan Adams, Penelope Markham
Journal: Journal of Hepatology (2020)
Hypertension Control for 10 Million
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TO TRY THE SERUM.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acknowledgement
Authors: Giovanni A. Fava, Nicoleta Sonino, Murray A. Morphy, P. Salmaggi, G.M. Bressa, G. Nicchia, M. Coniglio, P. La Greca, C. Le Grazie, Jerald F. Dirks, Jeffrey Wunder, Robert Kinsman, Joseph McElhinny, Nelson F. Jones, P. Bech, Diane S. Berry, James W. Pennebaker
Journal: Psychotherapy and Psychosomatics (1993)
Principles for graduate medical education. Council on Medical Education
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smallpox Vaccine Adverse Events Monitoring and Response System for the First Stage of the Smallpox Vaccination Program
Journal: JAMA (2003)

Smallpox vaccination of civilian volunteer health-care workers began on January 24, 2003. As of February 4, a total of 37 states and counties have received shipments of smallpox vaccine, and 18 states and counties have begun smallpox vaccination; no serious adverse events have been reported. To monitor the occurrence of adverse events associated with vaccination, both those expected on the basis of previous experience and possible new unexpected adverse events, CDC and state health departments have established the Smallpox Vaccine Adverse Events Monitoring and Response System. The system also will be used to monitor the effectiveness of contraindication screening, identify new contraindications, and coordinate the distribution of vaccinia immune globulin (VIG) and cidofovir to the civilian population. This notice describes the components of the system, delineates roles and responsibilities, and explains how data from the system will be compiled and communicated.
Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC)
Authors: Radwan Massoud, Rita Assi, Elie Fares, Nabila Kreidieh, Rami Mahfouz, Souha Kanj, Aline El-Zakhem, Mohamed A. Kharfan-Dabaja, Ali Bazarbachi, Jean El Cheikh
Journal: Blood (2016)
Optimum Care for Hopelessly Ill Patients
Journal: New England Journal of Medicine (1976)

When advance life support and maximum therapeutic efforts are continued in a patient who is judged to be hopelessly ill and the anticipated outcome is death, serious medical, emotional, legal and economic questions concerning the justification for continued efforts arise.1 2 3 4 5 The responsible physician and the medical and nursing staff in the intensive-care unit (ICU) as well as the patient's relatives face the dilemma of deciding whether continued maximal efforts constitute a reasonable attempt at prolonging life or whether the patient's illness has reached a stage where further intensive care is, in fact, merely postponing death. Although relatively few such patients . . .
Abstract 18408: Cortical Spreading Depolarizations After Cardiac Arrest in an Asphyxial Rat Model
Authors: Frederik B Hansen, Niels Secher, Leif Østergaard, Morten Skovgaard, Else Tønnesen, Asger Granfeldt
Journal: Circulation (2015)

Introduction: Delayed neuronal cell death is observed following cardiac arrest (CA). The exact mechanisms remain unknown. Cortical spreading depolarization (CSD) is characterized by depolarization of neurons and glia cells, spreading as a wave that travels across the cortex. CSDs are known to occur in peri-infarct tissue and have been associated with poor outcome after stroke, and might contribute to the progression of neuronal injury after CA. Objective: To investigate if spontaneous CSDs occur during the post resuscitation period following CA, and to describe the characteristics of induced CSDs. Methods: Isoflurane-anesthetized Sprague-Dawley rats were randomized into one control group observed for 90 min (n=8), and two CA groups observed for 90 min (CA90min, n=7) and 360 min (CA360min, n=7), respectively, before data collection started. Animals underwent 8 min of asphyxial CA. Electrophysiological recordings were obtained over the right hemisphere through a burr hole. Potassium chloride (KCL) was applied onto the cortex through a separate burr hole in order to induce CSDs. Direct current recordings were gathered using an AgCl glass electrode. Induced abnormal CSDs were defined as CSDs with prolonged duration, low peak value, altered propagation speed and/or epileptiform discharges. Data collection (210 min) was divided into two periods: 1) In the 1 st period no stimulation was applied in order to detect spontaneous elicited CSDs. 2) In the 2 nd period KCl was applied. Results: Spontaneous CSDs were observed in one CA360min animal with prolonged CPR and time to return of spontaneous circulation of 298 sec. Significantly fewer CSDs were induced following KCl application in CA animals when compared with healthy controls (median(IQR) Control: 6(5-7) CA90min: 2(1-4) CA360min: 1(1-3), p&lt;0.05). Induced abnormal CSDs were seen in both CA groups but not in controls (control vs. CA90min p=0.004, control vs. CA360min p=0.054). KCl application elicited multiple CSDs in rapid succession in 50% of CA animals and none of the controls (p=0.052). Conclusion: CSDs can occur following prolonged CA and resuscitation, and may lead to additional neuronal injury. The appearance and number of induced CSDs were altered in CA animals in comparison with healthy controls.
Rofecoxib associated with weekly irinotecan and infusional 5-fluorouracil as second-line treatment for metastatic colorectal cancer
Authors: G. Gasparini, D. Gattuso, A. Morabito, G. Carillio, S. Vitale, M. Fanelli, F. Torino, P. Bonginelli, M. A. Castellana, L. De Sio
Journal: Journal of Clinical Oncology (2004)

3686 Background:We performed this Phase I –II study to determine the feasibility and activity of a “methronomic” schedule of chemotherapy with weekly irinotecan (CPT 11) and 5-fluorouracil (5-FU) by continuos infusion associated with a selective inhibitor of cyclooxygenase-2 (COX-2) as second-line therapy for advanced colorectal cancer. Methods:The patients (pts) had metastatic disease progressing after an oxaliplatin-based chemotherapy, age ≥ 18 to ≤ 75 years, good performance status and measurable lesions. A cycle of treatment consisted of two phases: induction (weeks 1 to 5), with rofecoxib at the oral dose of 50 mg/day combined with intravenous weekly CPT-11 on days 1–8-15–22 and infusional 5-FU at the dose of 200 mg/m2/day for 5 weeks, and maintenance (weeks 6 to 8) with rofecoxib alone. The starting dose of CPT-11 was of 87.5 mg/m2, further dose escalations were by increments of 12.5 mg/m2 per level up to 125 mg/m2. Results: Fifteen pts have been enrolled in the Phase I study. The dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) were defined by conventional criteria. At the fourth dose level (125 mg/m2) a pt out of the 6 enrolled presented grade 3 reversible diarrhea as one DLT. During the 35 cycles administered, side-effects were moderate, only 7 being complicated by grade 3–4 toxicities. Therefore the dose of the irinotecan of 125 mg/m2 was closen for the Phase II study. Seven of the 15 assessable pts obtained a partial response (46.7%; 95% exact confidence limits: 21 to 71%) with a median duration of 5 months. Thirty-two pts have been enrolled up to now into the Phase II and 26 are evaluable for toxicity and response. No complete response was observed: 11 pts had partial response (42.3 % ) and 10 stable disease (38,5 %). To date, grade 3 diarrhea in 6 pts, grade 3–4 neutropenia in 5 pts, and grade 3 peripheral neuropathy in 1 pt were observed. Conclusions: Rofecoxib associated with weekly irinotecan and infusional 5-fluorouracil is a safe and active second line treatment for metastatic colorectal cancer. The recruitment is ongoing. No significant financial relationships to disclose.
A man with intermittent fever and arthralgia
Authors: M. QUINN, A. GOUGH;, D. SYMMONS, S M KNIGHT
Journal: Annals of the Rheumatic Diseases (1999)

Cladribine in the treatment of systemic lupus erythematosus nephritisSystemic lupus erythematosus (SLE) nephritis often requires treatment with cyclophosphamide, which carries the risk of major side eVects including infection, ovarian failure and bladder malignancy.Therapeutic strategies that would specifically target lymphocytes are appealing.Following the first report of the use of the purine nucleoside analogue cladribine (2-chloro-2'deoxyadenosine), a selective lymphocyte depleting agent, in the treatment of lupus nephritis, 1 we report our experience in two patients with severe renal involvement.
HIV therapeutics: an emerging science
Authors: J. A. Bartlett
Journal: JAMA (1988)

Between 1 and 2 million Americans are infected with the human immunodeficiency virus (HIV).<sup>1</sup>Available evidence suggests that most, if not all, will ultimately develop the acquired immunodeficiency syndrome (AIDS) within a projected mean of eight years after HIV acquistion.<sup>2</sup>Clearly, the need is great for HIV-directed therapy. Due to the ability of HIV to establish latent infection within cells, therapy must be considered as lifelong in duration with a "cure" unlikely in the near future. Therefore, the goals of therapy for now must be to improve the quality and quantity of life for persons with AIDS and to prevent disease progression in persons with AIDS-related complex (ARC) and asymptomatic HIV infection. Potential therapeutic agents for HIV infection must surmount major hurdles, including control of latent virus infection, central nervous system penetration, and the rapid development of viral variants. These agents are then administered to persons with ARC
Central Stimulation of Respiration and Circulation in Gynecologic and Obstetric Surgery and in Asphyxia of the Newborn
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal